Global Medical Grants; Request for Proposals (RFP). Understanding Residual Cardiovascular Risk Related to Triglyceride-Rich Remnant Lipoproteins

I. Background
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses
an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP. For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the
independent education program.

Date RFP Issued: December 10, 2020

Geographic Scope: Global

Clinical Area: Residual cardiovascular risk 

Link to full RFP: Understanding Residual Cardiovascular Risk Related to Triglyceride-Rich Remnant Lipoproteins

Application Due Date: February 18, 2021

Specific Area of Interest: Through this RFP, it is our intention to support educational programs focused on understanding residual cardiovascular (CV) risk associated with triglyceride (TG)-rich remnant lipoproteins by:

• Discussing the importance of understanding sources of CV risk beyond LDL-C
• Discussing relevant basic and clinical science related to TG-rich remnant lipoproteins versus serum TG in atherosclerosis and CV risk
• Providing context for clinicians to use this information in clinical practice where appropriate